General
Preferred name
ANASTROZOLE
Synonyms
ZD1033 ()
Arimidex,ZD-1033 ()
Anastrozole (ZD-1033) ()
ArimidexZD1033ICI D1033AnastrozoleArimidex (Zeneca).alpha.,alpha.,.alpha.',.alpha.'-tetramethyl-5(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrileANAS1,3-Benzenediacetonitrile,.alpha.,alpha.,alpha.',.alpha.'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)- ()
Anastrozol ()
NSC-719344 ()
NSC-759855 ()
ICI D1033 ()
ZD-1033 ()
Rvg-106400 ()
Arimidex ()
Nastrosa ()
ICI-D1033 ()
Anastrozole-d12 ()
P&D ID
PD003143
CAS
120511-73-1
120512-32-5
Tags
available
drug
Approved by
FDA
First approval
1995
Drug indication
Breast cancer
breast carcinoma
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Anastrozole decreases the amount of estrogens that the body makes by inhibiting the enzyme aromatase, which is responsible for converting androgens to estrogens in females. (GtoPdb)
DESCRIPTION Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM.
PRICE 37
DESCRIPTION Selective FAK inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Potent aromatase (CYP19) inhibitor (Tocriscreen Plus)
DESCRIPTION Anastrozole is a competitive, selective, non-steroidal aromatase inhibitor. Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive locally advanced or metastatic breast cancer in postmenopausal women. (Enamine Bioactive Compounds)
DESCRIPTION Anastrozole (ZD1033)(ZD1033), a potent and highly selective aromatase (CYP19) inhibitor (IC50 = 15 nM), has no obvious effect on adrenocorticoid hormone synthesis. (TargetMol Bioactive Compound Library)
Compound Sets
37
AdooQ Bioactive Compound Library
A10075
Axon Medchem Screening Library
3316
Cayman Chemical Bioactives
11987
25360
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1399
ChEMBL Drugs
CHEMBL1399
Concise Guide to Pharmacology 2017/18
5137
Concise Guide to Pharmacology 2019/20
5137
Concise Guide to Pharmacology 2021/22
5137
Concise Guide to Pharmacology 2023/24
5137
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01217
DrugBank Approved Drugs
DB01217
DrugCentral
210
DrugCentral Approved Drugs
210
DrugMAP
DMNP60F
DrugMAP Approved Drugs
DMNP60F
DrugMatrix
Enamine Bioactive Compounds
EBC-06099
Enamine BioReference Compounds
Guide to Pharmacology
5137
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1399
Mcule NIBR MoA Box Subset
MCULE-3029589501
MedChem Express Bioactive Compound Library
HY-14274
NCATS Inxight Approved Drugs
2Z07MYW1AZ
NIH Approved Oncology Drugs
535026
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Anastrozole
TargetMol Bioactive Compound Library
T0393
The Spectrum Collection
Tocris Bioactive Compound Library
3388
Tocriscreen Plus
3388
External IDs
48
Properties
(calculated by RDKit )
Molecular Weight
293.16
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
2.93
TPSA
78.29
Fraction CSP3
0.41
Chiral centers
0.0
Largest ring
6.0
QED
0.87
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
MOA
Aromatase inhibitor
Inhibitor
Aromatase Inhibitors
Target
Cytochrome P450 19A1
Aromatase
CYP19A1
Primary Target
Cytochrome P450
Member status
virtual
Indication
breast cancer
Therapeutic Class
Anticancer Agents
Pathway
Metabolic Enzyme/Protease
Endocrinology/Hormones
Source data